Muscular Dystrophy – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of muscular dystrophy for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology’s muscular dystrophy forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of muscular dystrophy over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following muscular dystrophy patient populations:

  • Diagnosed incidence of Duchenne muscular dystrophy (DMD).
  • Diagnosed prevalence of Becker muscular dystrophy.
  • Diagnosed prevalence of congenital muscular dystrophy.
  • Diagnosed prevalence of distal muscular dystrophy.
  • Diagnosed prevalence of DMD.
  • Diagnosed prevalence of Emery-Dreifuss muscular dystrophy.
  • Diagnosed prevalence offacioscapulohumeral muscular dystrophy.
  • Diagnosed prevalence of limb-girdle muscular dystrophy.
  • Diagnosed prevalence of myotonic dystrophy.
  • Diagnosed prevalence ofoculopharyngeal muscular dystrophy.
  • Diagnosed prevalenceofDMD by ambulation.
  • Diagnosed prevalence of DMDamenable to exon-skipping therapy.
  • Diagnosed prevalenceofDMD by nonsense mutations.

Note: Coverage may vary by country and region.

Table of contents

  • Muscular Dystrophy - Epidemiology - Mature Markets
    • Introduction
      • Diagnosed Prevalence of Duchenne Muscular Dystrophy per 100,000 Males in 2019 and 2039
      • Relative Sizes of Contributing Factors to the Trend in Prevalent Cases of Duchenne Muscular Dystrophy over the Next 20 Years
      • Percentage of Diagnosed Prevalent Cases of Duchenne Muscular Dystrophy by Exon-Skipping Pattern
      • Analysis of the Prevalent Cases of Duchenne Muscular Dystrophy in 2019 by Ambulation Status
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases of Duchenne Muscular Dystrophy
      • Diagnosed Prevalent Cases of Duchenne Muscular Dystrophy by Exon-Skipping Pattern
      • Diagnosed Prevalent Cases of Duchenne Muscular Dystrophy by Ambulatory Status
      • Diagnosed Prevalent Cases of Duchenne Muscular Dystrophy by Nonsense Mutation Status
      • Diagnosed Incident Cases of Duchenne Muscular Dystrophy
      • Diagnosed Prevalent Cases of Myotonic Dystrophy
      • Diagnosed Prevalent Cases of Myotonic Dystrophy Type 1
      • Diagnosed Prevalent Cases of Myotonic Dystrophy Type 1 by Subtype
      • Diagnosed Prevalent Cases of Myotonic Dystrophy Type 2
      • Diagnosed Prevalent Cases of Congenital Muscular Dystrophy
      • Diagnosed Prevalent Cases of Congenital Muscular Dystrophy by Subtype
      • Diagnosed Prevalent Cases of Facioscapulohumeral Muscular Dystrophy
      • Diagnosed Prevalent Cases of Distal Muscular Dystrophy
      • Diagnosed Prevalent Cases of Oculopharyngeal Muscular Dystrophy
      • Diagnosed Prevalent Cases of Emery-Dreifuss Muscular Dystrophy (X-Linked)
      • Diagnosed Prevalent Cases of Becker Muscular Dystrophy
      • Diagnosed Prevalent Cases of Limb-Girdle Muscular Dystrophy
      • Drug-Treated Prevalent Cases of Duchenne Muscular Dystrophy
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Muscular Dystrophy
        • Studies Excluded from the Analysis of Muscular Dystrophy
      • Risk/Protective Factors
        • Risk/Protective Factors for Muscular Dystrophy
      • Bibliography